Nicotinamide (DrugBank: Nicotinamide)
6 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
2 | 筋萎縮性側索硬化症 | 1 |
6 | パーキンソン病 | 3 |
18 | 脊髄小脳変性症(多系統萎縮症を除く。) | 6 |
49 | 全身性エリテマトーデス | 1 |
162 | 類天疱瘡(後天性表皮水疱症を含む。) | 1 |
191 | ウェルナー症候群 | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04562831 (ClinicalTrials.gov) | October 7, 2020 | 10/9/2020 | The NO-ALS Study: A Trial of Nicotinamide/Pterostilbene Supplement in ALS. | A Randomized Placebo-controlled Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS Study | Amyotrophic Lateral Sclerosis | Dietary Supplement: EH301 (Nicotinamide Riboside/Pterostilbene) | Haukeland University Hospital | NULL | Recruiting | 35 Years | N/A | All | 380 | N/A | Norway |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03568968 (ClinicalTrials.gov) | May 15, 2020 | 14/6/2018 | A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease | A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease: the NOPARK Study | Parkinson Disease | Dietary Supplement: Nicotinamide Riboside;Drug: Placebo | Haukeland University Hospital | NULL | Recruiting | 18 Years | N/A | All | 400 | N/A | Norway |
2 | NCT03816020 (ClinicalTrials.gov) | March 9, 2019 | 7/12/2018 | NAD-supplementation in Drug naïve Parkinson's Disease | NAD-PARK: A Double-blinded Randomized Pilot Trial of NAD-supplementation in Drug naïve Parkinson's Disease | Parkinson Disease;Neurodegenerative Diseases | Dietary Supplement: Nicotinamide Riboside;Other: Placebo | Haukeland University Hospital | NULL | Completed | 18 Years | N/A | All | 30 | N/A | Norway |
3 | EUCTR2004-005034-39-GB (EUCTR) | 17/05/2005 | 20/04/2005 | Nicotinamide,vitamin B3, metabolic pathways in patients with early idiopathic parkinson's disease | Nicotinamide,vitamin B3, metabolic pathways in patients with early idiopathic parkinson's disease | Idiopathic Parkinson's disease | Trade Name: Nicotinamide Product Name: NICOTINAMIDE INN or Proposed INN: Nicotinamide | Queen Elizabeth Hospital | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | United Kingdom |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04192136 (ClinicalTrials.gov) | September 3, 2020 | 6/12/2019 | NAD+ and Exercise in FA | NAD+ Precursor Supplementation With Exercise Training to Increase Aerobic Capacity in Friedreich's Ataxia | Friedreich Ataxia 1 | Dietary Supplement: Nicotinamide Riboside;Dietary Supplement: Placebo;Other: Exercise Intervention | Children's Hospital of Philadelphia | National Institutes of Health (NIH) | Recruiting | 10 Years | 40 Years | All | 72 | N/A | United States |
2 | EUCTR2017-002163-17-ES (EUCTR) | 08/04/2020 | 23/01/2020 | MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF NICOTINAMIDE IN PATIENTS WITH FRIEDREICHS ATAXIA. | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF NICOTINAMIDE IN PATIENTS WITH FRIEDREICHS ATAXIA. - NICOFA | Friedreich Ataxia;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Nicotinamide INN or Proposed INN: NICOTINAMIDE | RWTH Aachen University represented by the Rector himself, represented by the Dean of the Medical Faculty | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 225 | Phase 2;Phase 3 | Spain;Austria;Germany;United Kingdom | ||
3 | NCT03761511 (ClinicalTrials.gov) | March 2020 | 27/11/2018 | Study of the Efficacy and Safety of Nicotinamide in Patients With Friedreich Ataxia | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study of the Efficacy and Safety of Nicotinamide in Patients With Friedreich Ataxia | Friedreich Ataxia | Drug: Nicotinamide;Drug: Placebo | RWTH Aachen University | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | 18 Years | N/A | All | 225 | Phase 2 | Austria;France;Germany;Italy;Spain;United Kingdom |
4 | EUCTR2017-002163-17-GB (EUCTR) | 21/01/2020 | 31/10/2019 | Use of Nicotinamide for the Treatment of Patients with Friedreich's Ataxia. | A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF NICOTINAMIDE IN PATIENTS WITH FRIEDREICH´S ATAXIA (NICOFA) - NICOFA | Friedreich's ataxia.Friedreich ataxia is the most frequent early-onset autosomal recessive hereditary ataxia. It is caused by a pathological expansion of a GAA repeat in the first intron of the frataxin gene (FXN) and results in decreased levels of FXN protein. FXN deficiency results in a relentlessly progressive neurodegenerative condition which frequently presents around puberty. Patients gradually lose coordination, become dysarthric and are frequently wheelchair-bound as adolescents. MedDRA version: 20.0;Level: PT;Classification code 10017374;Term: Friedreich's ataxia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Nicotinamide Product Name: Nicotinamide INN or Proposed INN: Nicotinamide Other descriptive name: SUB09246MIG | RWTH Aachen University, Center for Translational & Clinical Research Aachen (CTC-A) | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 225 | Phase 2;Phase 3 | Spain;Austria;Germany;United Kingdom | ||
5 | EUCTR2017-002163-17-AT (EUCTR) | 04/09/2019 | 01/08/2019 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF NICOTINAMIDE IN PATIENTS WITH FRIEDREICHS ATAXIA. | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF NICOTINAMIDE IN PATIENTS WITH FRIEDREICHS ATAXIA. - NICOFA | Friedreich Ataxia;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Nicotinamide INN or Proposed INN: NICOTINAMIDE | RWTH Aachen University represented by the Rector himself, represented by the Dean of the Medical Faculty | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 225 | Phase 2;Phase 3 | Austria;Germany | ||
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
6 | EUCTR2017-002163-17-DE (EUCTR) | 25/10/2018 | 20/11/2017 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF NICOTINAMIDE IN PATIENTS WITH FRIEDREICHS ATAXIA. | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF NICOTINAMIDE IN PATIENTS WITH FRIEDREICHS ATAXIA. - NICOFA | Friedreich Ataxia;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Nicotinamide INN or Proposed INN: NICOTINAMIDE | RWTH Aachen University represented by the Center for Translational & Clinical Research Aachen (CTC-A) | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 225 | Phase 2;Phase 3 | Spain;Austria;Germany;United Kingdom |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03260166 (ClinicalTrials.gov) | August 31, 2017 | 10/8/2017 | Nicotinamide Treatment for Lupus-associated Skin Lesions in Lupus Erythematosus | An Open-label Study for Assessing the Efficacy and Safety of Nicotinamide Treatment for Lupus-associated Skin Lesions in Patients With Cutaneous Lupus Erythematosus or Systemic Lupus Erythematosus | Cutaneous Lupus Erythematosus;Systemic Lupus Erythematosus Rash | Drug: nicotinamide | Second Xiangya Hospital of Central South University | National Natural Science Foundation of China;Hunan Provincial Natural Science Foundation of China;National Key Clinical Specialty Construction Project of China | Recruiting | 18 Years | 65 Years | All | 40 | Phase 2 | China |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ChiCTR-TRC-12003592 | 2011-08-01 | 2012-12-30 | Use of Tripterygium glycosides and Nicotinamide plus Minocycline for the Treatment of bullous pemphigoid: A multicenter,randomized and controlled clinincal trial | Guideline-oriented Research in the Management of Some Common and Severe Skin Diseases | Bullous pemphigoid | Tripterygium glycosides group:Take tripterygium glycosides orally at 20 mg, 3 times a day;Nicotinamide plus Minocycline group:Take nicotinamide at 500 mg, 3 times a day and minocycline 100 mg, twice a day.; | Institute of dermatology, Chinese Academy of Medical Sciences | NULL | Completed | 18 | Both | Tripterygium glycosides group:100;Nicotinamide plus Minocycline group:100; | China |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | JPRN-jRCTs031190141 | 27/11/2019 | 27/11/2019 | Cross-over trial to verify safety and effectiveness of nicotinamide riboside and pterostilbene for patients with Werner syndrome | Prospective, single-center, cross-over trial to verify safety and effectiveness of nicotinamide riboside and pterostilbene for patients with Werner syndrome - EMPOWER | Werner syndrome Werner syndrome;C16.320.925 / C18.452.284.960 | Subjects ingest oral capsules of NRPT (nicotinamide riboside and pterostilbene) once daily (total daily dose: nicotinamide riboside 500 mg and pterostilbene 100mg) and placebo capsules for 6 months each in a randomly determined order. | Yokote Koutaro | NULL | Recruiting | >= 20age old | Not applicable | Both | 30 | Japan |